Janssen Pharmaceuticals Forms Partnerships with CureVac and DCPrime - - BioPharm International

ADVERTISEMENT

Janssen Pharmaceuticals Forms Partnerships with CureVac and DCPrime



Jassen Pharmaceuticals has formed two separate vaccine pacts respectively with CureVac, a clinical-stage biopharmaceutical company, and DCPrime, a cancer vaccine company. Under the first deal, CureVac has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, a Johnson and Johnson company. Under the agreement CureVac will collaborate with Crucell Holland BV, a member of Janssen Pharmaceuticals, on the development of an influenza vaccine based on CureVac’s RNActive technology. RNActive vaccines, using CureVac‘s technology platform, have shown effectiveness and safety in several clinical trials.  Under the collaboration, CureVac will develop optimized RNActive vaccines based on Crucell’s proprietary antigen sequences that will be tested in various models.

In the other pact, DCPrime has entered into a research and optional license agreement with Janssen Pharmaceuticals. The collaboration has been facilitated in conjunction with the Johnson & Johnson London Innovation Center, where a team of business, science, and transaction experts are identifying and building early-stage collaborations with emerging companies. Under the agreement, Janssen will use DCPrime’s DCOne technology in feasibility studies for the development of a dendritic cell-based vaccine. Additionally, Janssen will have the option to further develop a candidate therapeutic towards regulatory approval.

 

Source: CureVac and DCPrime

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here